Ginsenoside Rg3 suppresses FUT4 expression through inhibiting NF-κB/p65 signaling pathway to promote melanoma cell death

International Journal of Oncology

Volumn 47, Issue 2, 2015, Pages 701-709

  Shan, Xiu ^a   Tian, Li Li ^a   Zhang, Yu Mei ^a   Wang, Xiao Qi ^b   Yan, Qiu ^a   Liu, Ji Wei ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Apoptosis; Fucosyltransferase IV; Melanoma; NF B; Rg3

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ANTINEOPLASTIC AGENT; DNA; FUCOSYLTRANSFERASE; FUCOSYLTRANSFERASE 4; GINSENOSIDE RG 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; CD15 ANTIGEN; FUT4 PROTEIN, HUMAN; GINSENOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; BINDING SITE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; SKIN NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD15; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BINDING SITES; CELL LINE, TUMOR; CELL SURVIVAL; FUCOSYLTRANSFERASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GINSENOSIDES; HUMANS; MALE; MELANOMA; MICE; NF-KAPPA B; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84932631859     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3057     Document Type: Article

References (39)

1. McGettigan S: Dabrafenib: A new therapy for use in BRAFmutated metastatic melanoma. J Adv Pract Oncol 5: 211-215, 2014.
2. Lens MB and Dawes M: Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150: 179-185, 2004.
3. Rigel DS, Russak J and Friedman R: The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin 60: 301-316, 2010.
4. Menaa F: Latest approved therapies for metastatic melanoma: What comes next? J Skin Cancer 2013: 735282, 2013.
5. Graham B and Gibson SB: The two faces of NFkappaB in cell survival responses. Cell Cycle 4: 1342-1345, 2005.
6. Kiernan R, Brès V, Ng RWM, Coudart MP, El Messaoudi S, Sardet C, Jin DY, Emiliani S and Benkirane M: Post-activation turn-off of NF-B-dependent transcription is regulated by acetylation of p65. J Biol Chem 278: 2758-2766, 2003.
7. Doyle SL and O'Neill LA: Toll-like receptors: From the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 72: 1102-1113, 2006.
8. Perkins ND and Gilmore TD: Good cop, bad cop: The different faces of NF-kappaB. Cell Death Differ 13: 759-772, 2006.
9. Kashani-Sabet M, Liu Y, Fong S, Desprez PY, Liu S, Tu G, Nosrati M, Handumrongkul C, Liggitt D, Thor AD, et al: Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc Natl Acad Sci USA 99: 3878-3883, 2002.
10. Kashani-Sabet M, Shaikh L, Miller JR III, Nosrati M, Ferreira CM, Debs RJ and Sagebiel RW: NF-kappa B in the vascular progression of melanoma. J Clin Oncol 22: 617-623, 2004.
11. Munshi A, Kurland JF, Nishikawa T, Chiao PJ, Andreeff M and Meyn RE: Inhibition of constitutively activated nuclear factorkappaB radiosensitizes human melanoma cells. Mol Cancer Ther 3: 985-992, 2004.
12. Ichikawa H, Takada Y, Shishodia S, Jayaprakasam B, Nair MG and Aggarwal BB: Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. Mol Cancer Ther 5: 1434-1445, 2006.
13. Fuster MM, Esko JD and Esko JD: The sweet and sour of cancer: Glycans as novel therapeutic targets. Nat Rev Cancer 5: 526-542, 2005.
14. Weston BW, Nair RP, Larsen RD and Lowe JB: Isolation of a novel human alpha (1,3)fucosyltransferase gene and molecular comparison to the human Lewis blood group alpha (1,3/1,4) fucosyltransferase gene. Syntenic, homologous, nonallelic genes encoding enzymes with distinct acceptor substrate specificities. J Biol Chem 267: 4152-4160, 1992.
15. Weston BW, Smith PL, Kelly RJ and Lowe JB: Molecular cloning of a fourth member of a human alpha (1,3)fucosyltransferase gene family. Multiple homologous sequences that determine expression of the Lewis x, sialyl Lewis x, and difucosyl sialyl Lewis x epitopes. J Biol Chem 267: 24575-24584, 1992.
16. Petretti T, Schulze B, Schlag PM and Kemmner W: Altered mRNA expression of glycosyltransferases in human gastric carcinomas. Biochim Biophys Acta 1428: 209-218, 1999.
17. Ito H, Hiraiwa N, Sawada-Kasugai M, Akamatsu S, Tachikawa T, Kasai Y, Akiyama S, Ito K, Takagi H and Kannagi R: Altered mRNA expression of specific molecular species of fucosyl-and sialyl-transferases in human colorectal cancer tissues. Int J Cancer 71: 556-564, 1997.
18. Ogawa J, Inoue H and Koide S: Expression of alpha-1,3-fucosyltransferase type IV and VII genes is related to poor prognosis in lung cancer. Cancer Res 56: 325-329, 1996.
19. Yang X, Zhang Z, Jia S, Liu Y, Wang X and Yan Q: Overexpression of fucosyltransferase IV in A431 cell line increases cell proliferation. Int J Biochem Cell Biol 39: 1722-1730, 2007.
20. Yang X, Liu S and Yan Q: Role of fucosyltransferase IV in epithelial-mesenchymal transition in breast cancer cells. Cell Death Dis 4: e735, 2013.
21. Yang X, Liu Y, Liu J, Wang X and Yan Q: Cyclophosphamideinduced apoptosis in A431 cells is inhibited by fucosyltransferase IV. J Cell Biochem 112: 1376-1383, 2011.
22. Yuan HD, Quan HY, Zhang Y, Kim SH and Chung SH: 20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon cancer cells is associated with AMPK signaling pathway. Mol Med Rep 3: 825-831, 2010.
23. Park EH, Kim YJ, Yamabe N, Park SH, Kim HK, Jang HJ, Kim JH, Cheon GJ, Ham J and Kang KS: Stereospecific anticancer effects of ginsenoside Rg3 epimers isolated from heat-processed American ginseng on human gastric cancer cell. J Ginseng Res 38: 22-27, 2014.
24. Kim SM, Lee SY, Cho JS, Son SM, Choi SS, Yun YP, Yoo HS, Yoon Y, Oh KW, Han SB, et al: Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB. Eur J Pharmacol 631: 1-9, 2010.
25. Lee CK, Park KK, Chung AS and Chung WY: Ginsenoside Rg3 enhances the chemosensitivity of tumors to cisplatin by reducing the basal level of nuclear factor erythroid 2-related factor 2-mediated heme oxygenase-1/NAD(P)H quinone oxidoreductase-1 and prevents normal tissue damage by scavenging cisplatin-induced intracellular reactive oxygen species. Food Chem Toxicol 50: 2565-2574, 2012.
26. Yu Y, Zhang C, Liu L and Li X: Hepatic arterial administration of ginsenoside Rg3 and transcatheter arterial embolization for the treatment of VX2 liver carcinomas. Exp Ther Med 5: 761-766, 2013.
27. Shan X, Aziz F, Tian LL, Wang XQ, Yan Q and Liu JW: Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation inhibits melanoma cell proliferation by decreasing FUT4/LeY expression. Int J Oncol 46: 1667-1676, 2015.
28. Wang JH, Nao JF, Zhang M and He P: 20(s)-ginsenoside Rg3 promotes apoptosis in human ovarian cancer HO-8910 cells through PI3K/Akt and XIAP pathways. Tumour Biol 35: 11985-11994, 2014.
29. Kim BM, Kim DH, Park JH, Surh YJ and Na HK: Ginsenoside Rg3 inhibits constitutive activation of NF-B signaling in human breast cancer (MDA-MB-231) cells: ERK and Akt as potential upstream targets. J Cancer Prev 19: 23-30, 2014.
30. Zhang Z, Sun P, Liu J, Fu L, Yan J, Liu Y, Yu L, Wang X and Yan Q: Suppression of FUT1/FUT4 expression by siRNA inhibits tumor growth. Biochim Biophys Acta 1783: 287-296, 2008.
31. Yang X, Wang J, Liu S and Yan Q: HSF1 and Sp1 regulate FUT4 gene expression and cell proliferation in breast cancer cells. J Cell Biochem 115: 168-178, 2014.
32. Hongyan L, Shaoming T and Qiu Y: Correlation between FUT4 expression and its promoter methylation in HaCaT cells. Yi Chuan 37: 48-54, 2015.
33. Kim MK, Jeon YK, Woo JK, Choi Y, Choi DH, Kim YH and Kim CW: The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-B activity and down-regulating Bfl-1. Mol Cancer 10: 98, 2011.
34. Brandi G, Pantaleo MA, Biasco G and Paterini P: Activated NF-B in colorectal cancer: Predictive or prognostic factor J Clin Oncol 26: 1388-1389, author reply 1389-1390, 2008.
35. Richmond A: NF-B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2: 664-674, 2002.
36. Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002.
37. Melnikova VO and Bar-Eli M: Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther 7: 997-1003, 2008.
38. Heon Seo K, Ko HM, Kim HA, Choi JH, Jun Park S, Kim KJ, Lee HK and Im SY: Platelet-activating factor induces up-regulation of antiapoptotic factors in a melanoma cell line through nuclear factor-kappaB activation. Cancer Res 66: 4681-4686, 2006.
39. Cheng L, Luo S, Jin C, Ma H, Zhou H and Jia L: FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell Death Dis 4: e923, 2013.